Background {#Sec1}
==========

Coenzyme Q~10~ (CoQ~10~ or ubiquinone) is a lipid-soluble component of the mitochondrial inner membrane that plays a central role in mitochondrial respiratory chain (MRC) function, as electrons carrier from complexes I and II to complex III, thus participating in ATP production \[[@CR1]\].

CoQ~10~ deficiency encompasses several clinical phenotypes such as encephalomyopathy, severe infantile multisystemic disease, cerebellar ataxia, isolated myopathy or nephrotic syndrome \[[@CR2]\]. CoQ~10~ deficiency can be primary, due to mutations in genes involved in CoQ~10~ biosynthesis or secondary, due to mutations in genes unrelated to CoQ~10~ biosynthesis \[[@CR3]\]. Secondary CoQ~10~ deficiency has been described in patients with mitochondrial DNA (mtDNA) mutations or deletions, with mtDNA depletion syndrome (MDS) \[[@CR4]--[@CR6]\] and in patients with mutations in *APTX* \[[@CR7]\], *ETFDH* \[[@CR8], [@CR9]\], *BRAF* \[[@CR10]\], *ACADVL* or *NPC* genes \[[@CR11]\]. CoQ~10~ defect is the only oxidative phosphorylation (OXPHOS) disorder that can be clinically improved after oral CoQ~10~ supplementation with limitation of neurological and renal manifestations, amelioration of muscular symptoms and attenuation of histological alterations. Early treatment is crucial to prevent irreversible damage in organs such as the kidney and the central nervous system \[[@CR12]--[@CR14]\]. Reduced activities of CoQ~10~-dependent enzymes by spectrophotometric analysis (segments I + III or G3P + III and II + III) are evocative of CoQ~10~ deficiency but direct measurement of CoQ~10~ levels is the most reliable test for diagnosis \[[@CR15]\]. It is widely reported in the literature that, in patients with CoQ~10~ deficiency, enzymatic activities of MRC complexes I, II, III, IV, V are normal \[[@CR16]\]. In a previous report, we described an 11-year-old boy presenting with a propionic acidemia who succumbed to acute heart failure in the absence of decompensation of his metabolic condition. Spectrophotometric analysis in liver identified CoQ~10~-dependent activities deficiency that was associated with MRC enzymatic defect. Secondary CoQ~10~ deficiency was likely involved in the development of heart complications in this child and we hypothesized that a CoQ~10~-defect may be associated with MRC deficiency \[[@CR17]\]. The aim of this study was to verify this hypothesis in order to improve the diagnosis of this disease.

Over a 6-year period, we analyzed by spectrophotometry 700 tissue samples from 495 patients in whom a mitochondrial disease was suspected. Isolated CoQ~10~-dependent activity deficiency led to identification of CoQ~10~ disease in eight cases. Eighteen patients presented CoQ~10~-dependent enzymatic deficiency associated with MRC defect by spectrophotometry in muscle or in fibroblasts. In order to validate our original observation and to establish if CoQ~10~ quantitative defect may be associated with multiple MRC enzymatic deficiency, we measured CoQ~10~ in this group of 18 patients. We found decreased CoQ~10~ levels by liquid chromatography coupled with tandem mass spectrometry detection (LC-MSMS) in eight patients out of 18 (45 %), thus confirming CoQ~10~ disease and its association with MRC enzymatic deficiency. Furthermore, CoQ~10~ disease cannot be ruled out in all other patients insofar as the quantitative assay could not always be performed in the affected tissue.

Results {#Sec2}
=======

Description of patients involved in the study {#Sec3}
---------------------------------------------

We studied 18 patients, including 10 males and eight females, ranging in age from day 1 to 76 years. Clinical presentations were very heterogeneous (Table [1](#Tab1){ref-type="table"}). The age at onset of the disease was highly variable, ranging from (i) neonatal forms (seven cases with severe phenotypes), (ii) onset before 1 year of age (four cases with either Leigh syndrome or epileptic encephalopathy), (iii) childhood-onset (four cases including two myopathic forms and two complex phenotypes) to (iv) adult-onset (three cases with two myopathic presentations and one cerebellar ataxia). The 18 patients were divided into two different groups according to molecular results.Table 1Clinical phenotypes of patients presenting CoQ~10~-dependent enzymatic deficiency associated with MRC defectPatientTissueSexAge at biopsyAge of onsetHeredityFamilial historyNeurological symptomsMuscular symptomsOther symptomsMuscle histologyEnzymologyDiagnosis or molecular analyses*Patients with molecular diagnosis*P01^a^FibroblastsMD1NeonatalRecessiveAffected brotherNeonatal polyvisceral failureNot doneCx IV deficiency; segments II + III and G3P + III reduction*COQ2*: homozygous mutation (c.437G \> A; p.Ser146Asn)P02MuscleM54y25ySporadicNoBrain MRI: mild atrophy and lacunar strokesCPEOT2DM, hepatic steatosis, dyslipidemiaRRF (5--10 %) and Cox-fibersCxes I, II, IV and V deficiency; segments I + III and II + III reductionLarge-scale deletion of mtDNAP03^a^FibroblastsMD1Neonatal*de novo*NoHypotonia, epilepsy and diffuse brain lesionsNeonatal polyvisceral failure: respiratory distress, hepatic failure, hypertrophic CMP, lactic acidosis ++Not doneCxes II and III deficiency; segments II + III and G3P + III reduction*MT*-*CYB*: heteroplasmic mtDNA mutation (m.15635T \> C; p.Ser297Pro)P04^a^FibroblastsM15y11yRecessiveNoAtaxic sensory axonal neuropathyCPEORRF and Cox-fibers (40 %)Cxes I, II, III and IV deficiency; segments II + III and G3P + III reductionSANDO with multiple mtDNA deletions and homozygous mutation in *POLG*: (c.911T \> G; p.Leu304Arg)P05MuscleF54y45yRecessiveNoAtaxic sensory axonal neuropathyCPEOLipid accumulation, RRF and Cox-fibers (20 %)Cxes I, II, III, IV and V deficiency; segments I + III and II + III reductionSANDO with multiple mtDNA deletions and compound heterozygous mutations in *POLG*: (c.752C \> T/c.2452G \> A; p.Thr251Ile/p.Gly848Ser)P06^a^FibroblastsMD1NeonatalRecessiveNoEncephalopathy and hypotoniaSevere lactic acidosis, methylmalonic aciduriaNot doneCxes II, III and IV deficiency; segments II + III and G3P + III reduction*SUCLG1*: compound heterozygous mutations c.97 + 3G \> C/c.509C \> G (p.Pro170Arg)P07MuscleF18y4yRecessiveBlindness in paternal familyBilateral ptosis, proximal myopathy, dysphonia, dysphagia, exercice intoleranceRetinitis pigmentosa, cyclic vomiting, hyperCPKemiaLipid accumulationCxes I and III deficiency; segments I + III and II + III reductionMADD with mutations in *ETFDH*P08MuscleF4 m4 mRecessiveAffected sisterEncephalopathy with refractory migrating partial seizuresLipid accumulationCx I, II, III and IV deficiency; segments I + III and II + III reductionMalignant migrating partial seizures with compound heterozygous mutations in *TBC1D24*: (c.468C \> A/c.686C \> T; p.Cys156X/p.Phe229Ser)P09FibroblastsMD1NeonatalRecessiveNoHypotoniaHypertrophic CMP, dysmorphic, hepatic cytolysis, hypospadiaGlycogenic accumulationCxes II, III, IV and V deficiency; segments II + III and G3P + III reductionCDG syndrome type Iq : homozygous mutation in *SRD5A3* : (c.620T \> G; p.Met207Arg)P10^a^FibroblastsM3 mNeonatal*de novo*NoHypotonia, epilepsy, dysphagiaDilated CMP, aortic dilatationGlycogenic accumulationCxes III and IV deficiency; segments II + III and G3P + III reduction1p36 deletion syndrome*Patients with no molecular diagnosis*P11MuscleM76yAdult?NoCerebellar ataxia2 RRF and Cox- fibers (20-30 %)Cx IV deficiency; segments I + III and II + III reductionMultiple mtDNA deletionsP12^a^FibroblastsF7 m6 m?NoLeigh syndromeNot doneCx II deficiency; segments II + III and G3P + III reductionmtDNA depletion, absence of mtDNA and *POLG, SUCLA2, TK2* mutationP13^a^MuscleF41yChildhoodRecessiveConsanguinitySpastic tetraparesis, chorea, mental retardationMyopathyGlaucoma, cataract, lactic acidosisRRF ++ Cx I deficiency; segments I + III and II + III reductionAbsence of mtDNA and *POLG, OPA1, OPA3* mutationP14MuscleF33y6 m?NoEpilepsy, spastic diplegia, dystonia, dyskinesia, tremor1 Cox-fiberCxes III and V deficiency; segments I + III and II + III reductionAbsence of mtDNA and *POLG, TTC19, DYT5* mutationP15MuscleF28 yChildhoodRecessiveAffected siblingsEncephalopathy, mental retardationNormalCxes II, III and V deficiency; segments I + III and II + III reductionAbsence of mtDNA mutationP16FibroblastsM9yInfancy?NoPsychomotor retardation, behavior disorders, dystonia, dyspraxia and basal ganglia involvement at brain MRI (Leigh)NormalCxes II and III deficiency; segments II + III and G3P + III reductionAbsence of mtDNA mutationP17FibroblastsFD3D2?NoUnexplained severe respiratory failureNormalCxes II, III deficiency; segments II + III and G3P + III reductionAbsence of mtDNA mutationP18FibroblastsM2yD18?NoEncephalopathy with refractory epilepsyMicrocephalyNormalCxes III and IV deficiency; segments II + III and G3P + III reductionAbsence of mtDNA mutation*M* male, *F* female, *D* day, *m* month, *y* year, *CPK* Creatine PhosphoKinase, *CPEO* Chronic Progressive External Ophthalmoplegia, *T2DM* Type 2 Diabetes Mellitus, *CMP* CardioMyoPathy, *RRF* Ragged Red Fibers, *Cox* cytochrome *c* oxydase, *cx* complex, *mtDNA* mitochondrial DNA, *SANDO* Sensory Ataxia Neuropathy Dysarthria and Ophthalmoplegia, *MADD* Multiple Acyl-CoA Dehydrogenation Deficiency, *CDG* Carbohydrate-Deficient Glycoprotein^a^Patient deceased

The first group included 10 patients with identified mutations in responsible genes (Table [1](#Tab1){ref-type="table"}). Patient P01 presented a severe neonatal multisystemic disease secondary to a homozygous missense mutation in the *CoQ2* gene \[[@CR18]\]. Spectrophotometric analysis in fibroblasts revealed a CoQ~10~-dependent activities defect (segments II + III and G3P + III reduction) associated with a complex IV deficiency (Table [2](#Tab2){ref-type="table"}). Six patients (P02--P07) presented a mitochondrial disease or dysfunction secondary either to mtDNA abnormalities (P02 and P03) or to mutations in nuclear genes (P04--P07). Patient P02 had a large heteroplasmic mtDNA deletion responsible for Kearns--Sayre syndrome and patient P03 presented with a severe neonatal polyvisceral failure secondary to a heteroplasmic mtDNA mutation in the *MT*-*CYB* gene. Patients P04 and P05 presented with sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO) phenotype associated with recessive mutations in *POLG.* Patient P06 had a neonatal encephalopathy with lactic acidosis and mild methylmalonic aciduria linked to mutations in the *SUCLG1* gene. P07 had a diagnosis of multiple acyl-CoA dehydrogenation deficiency (MADD) with *ETFDH* mutation. The last three patients in the first group presented malignant migrating partial seizures with mutations in *TBC1D24* (P08), CDG syndrome type Iq with *SRD5A3*-*CDG* mutations (P09) and 1p36 deletion syndrome (P10). Patients P02--P10 had a CoQ~10~-dependent activities deficiency (segments I + III or G3P + III and II + III reduction) associated with a multiple MRC defect in muscle or in fibroblasts (Table [2](#Tab2){ref-type="table"}).Table 2Biochemical analysis of patient fibroblasts and muscle biopsiesOXPHOS activities (spectrophotometry)IIIIIIIVVG3P + IIIII + IIICSCoQ10 quantity (LC-MSMS)CoQ10*Fibroblast measurementsControl values (nmole/min/mg of proteins)9.0--27.121.0--54.062.0--176.2109.9--350.022.0--46.26.5--23.015.0--37.274.7--161.1Control values (pmole/mg of proteins)43.0--120.8*P0111.227.789.7*29.2*33.5*2.37.5*156.2P01*1.4*P0311.5*18.521.3*177.734.1*4.112.5*106.7P0365.4P04*7.518.640.2108.2*30.5*4.78.6*95.0P04*9.7*P0611.6*20.647.978.1*37.6*5.510.8*116.6P06*5.9*P0912.0*13.453.457.015.84.18.9*80.9P0962.0P1013.522.9*54.465.0*28.3*5.412.0*148.2P1055.9P1210.9*17.6*76.6173.325.0*4.410.1*102.5P1262.1P1611.2*20.757.4*134.938.3*6.114.5*124.0P16*5.7*P1712.9*20.061.5*181.729.3*5.614.7*130.3P1758.1P1814.422.5*39.478.9*39.3*5.513.2*147.0P1858.2*Muscle biopsy measurementsControl values (nmole/min/mg of proteins)11.0--32.022.0--65.0109.0--236.093.0-347.040.0--89.014.0--50.020.0--50.082.0--234.0Control values (pmole/mg of proteins)17.8 --22.2*P02*6.721.5*130.4*56.932.57.410.8*113.4P02*16.0*P05*5.721.228.959.412.710.915.2*122.2P0535.5P07*4.2*28.6*108.8*170.450.0*10.516.7*272.4P0725.9P08*10.914.1102.592.8*63.3*10.817.0*116.5P08*5.7*P1125.729.7157.6*80.2*45.0*13.619.6*109.9P11*6.2*P13*7.6*28.9112.7212.758.4*9.413.4*192.6P1322.4P1415.526.6*31.6*154.5*32.813.713.2*100.5P1422.2P1516.2*20.092.3*191.7*39.811.917.5*86.1P15*7.1*Respiratory chain enzyme activities were measured spectrophotometrically. Results are expressed as absolute values for controls or patients (in nanomoles of substrate per minute per milligram of protein). CoQ~10~ quantity was measured by LC-MSMS. Results are expressed as absolute values for controls or patients (in picomoles per milligram of protein). Abnormal values are shown in italics*OXPHOS* oxidative phosphorylation; *LC-MSMS* liquid chromatography coupled with tandem mass spectrometry detection

The second group included eight patients suspected of CoQ~10~ deficiency with an absence of molecular diagnosis. Except for individual P11, who developed cerebellar ataxia during adulthood, all patients had an early-onset disease ranging from neonatal period to childhood. They presented severe neurological symptoms including two Leigh syndromes (P12 and P16) and one child had an unexplained severe respiratory failure at birth (P17). In the second group, all patients presented a CoQ~10~-dependent enzymatic deficiency associated with MRC defect in muscle or in fibroblasts (Table [2](#Tab2){ref-type="table"}).

Confirmation of CoQ~10~disease in eight patients by CoQ~10~ quantification {#Sec4}
--------------------------------------------------------------------------

Quantitative analysis of CoQ~10~ in muscle or fibroblasts showed that eight patients presented CoQ~10~ content below normal values (Table [2](#Tab2){ref-type="table"}). CoQ~10~ defect was found in five patients out of 10 in the first group and in three patients out of eight in the second group. CoQ~10~-deficient individuals were six males and two females, ranging in age from day 1 to 76 years. The age of onset was highly variable, ranging from neonatal forms to diseases appearing after 25 years of age, although six patients had childhood onset. One patient (P01) presented a polyvisceral failure at birth and all the others had neurological symptoms either isolated or combined with muscular and/or other signs. In the first group, the very low CoQ~10~ level observed in the fibroblasts of patient P01 confirmed the primary CoQ~10~ defect associated with the c.437G \> A homozygous missense mutation (p.Ser146Asn) in the *CoQ2* gene, involved in CoQ~10~ biosynthesis \[[@CR18]\]. In the four other patients in the same group, CoQ~10~ defect was clearly secondary because the responsible genes were unrelated to CoQ~10~ biosynthesis. Three patients had a mitochondrial disease linked to a large mtDNA deletion (patient P02) or to mutations in *POLG* (patient P04) or *SUCLG1* (patient P06). Patient P08 alone did not have a mitochondrial disease, her encephalopathy with refractory malignant migrating partial seizures being linked to mutations in the *TBC1D24* gene. In the second group, low CoQ~10~ levels were found in three patients with no molecular diagnosis. Two patients were strongly suspected of having a mitochondrial disease: patient P11, who had a cerebellar ataxia with 20--30 % of COX-negative fibers and multiple mtDNA deletions in muscle, and patient P16 who presented with a Leigh syndrome. The last patient (P15) had an encephalopathy with intellectual disability but no histological sign of mitochondrial myopathy.

Discussion {#Sec5}
==========

While primary CoQ~10~ defects are rare, secondary defects have been observed in various pathologies. In a previous work, we suspected for the first time a secondary CoQ~10~ defect in a child with propionic acidemia, who succumbed to acute heart failure in the absence of decompensation of his metabolic condition \[[@CR17]\]. CoQ~10~ deficiency was not evoked at the outset because CoQ~10~-dependent activities deficiency was associated with multiple MRC deficiency in the liver of the patient and it had been widely reported that enzymatic activities of MRC complexes are normal in CoQ~10~ disease \[[@CR16]\]. However, it is likely that a secondary CoQ~10~ defect was involved in the development of heart complications leading to the child's death and that oral CoQ~10~ supplementation would have been able to prevent cardiac failure if results had been obtained before acute clinical aggravation. This hypothesis is supported by a recent study, which describes a successful reversal of propionic acidemia-associated cardiomyopathy after treatment \[[@CR19]\]. The child in this case presented with myocardial CoQ~10~ quantitative defect associated with signs of mitochondrial dysfunction such as enlarged mitochondria with atypical cristae and low MRC complex IV activity \[[@CR19]\]. Several studies performed on cellular models of CoQ~10~ defect suggested a possible association with mitochondrial dysfunction: *PDSS2* and *COQ9* mutant fibroblasts presented a markedly reduced ATP synthesis and *COQ2* mutant fibroblasts presented a partial defect in ATP synthesis, as well as significantly increased ROS production and oxidation of lipids and proteins \[[@CR20], [@CR21]\]. In 2013, Duberley and colleagues established the first pharmacologically-induced CoQ~10~ deficient cellular model in neuroblastoma-derived SH-SY5Y cells by using para-aminobenzoic acid (PABA). They showed that, after PABA treatment, SH-SY5Y cells presented a progressive decrease in the activities of CoQ~10~-dependent II + III segment but also a deficiency in MRC complexes I and IV. They also reported a concomitant decrease in the level of total cellular ATP with an increase of mitochondrial oxidative stress \[[@CR22]\]. Lastly, deficiency of complexes I, II, III and/or IV has also been previously reported in association with CoQ~10~ defect in the patient's fibroblasts, muscle or kidney \[[@CR8], [@CR11], [@CR18], [@CR23]\].

Today, in most diagnostic laboratories, a spectrophotometric deficiency in one or several MRC enzymes associated with a decrease in CoQ~10~-dependent activities is not considered to be a sign of a CoQ~10~ disease, leading to a possible under-estimation of the frequency of this disorder. With the aim of achieving a better diagnostic approach, we quantified CoQ~10~ by LC-MSMS in 18 patients presenting a CoQ~10~-dependent enzymatic deficiency associated with a MRC defect by spectrophotometry. CoQ~10~ quantitative analysis in muscle or in fibroblast cells confirmed CoQ~10~ disease in eight patients (45 %). These data show that a primary CoQ~10~ defect can be associated with MRC enzymatic deficiency because patient P01, who carried a deleterious homozygous mutation (c.437G \> A; p.Ser146Asn) in the *CoQ2* gene, also presented a complex IV deficiency in muscle. Our data also confirm that a secondary CoQ~10~ defect can be associated with mitochondrial disease. Indeed, three other patients with a low CoQ~10~ level presented a respiratory chain deficiency linked to mtDNA deletion (patient P02) or to mutations in *POLG* and *SUCLG1* genes (patients P04 and P06). Secondary CoQ~10~ defect has already been reported in patients with mitochondrial diseases or dysfunctions including Kearns--Sayre syndrome \[[@CR24]\], mtDNA depletion and PEO \[[@CR5]\] or mutations in *ETFDH* coding for electrontransferring-flavoprotein dehydrogenase and causing MADD \[[@CR8], [@CR9]\]. Secondary CoQ~10~ defect has also been described in non-mitochondrial disorders linked to genes such as *APTX* coding for aprataxin and causing ataxia occulomotor-apraxia \[[@CR7]\], *BRAF* coding for serine/threonine-protein kinase B-Raf and causing cardiofaciocutaneous syndrome \[[@CR10]\], *ACADVL* causing very long-chain Acyl-CoA dehydrogenase deficiency or *NPC* causing Niemann-Pick-type C disease \[[@CR11]\]. Here, we report for the first time a secondary CoQ~10~ defect associated with mutations in the *TBC1D24* gene, leading to malignant migrating partial seizures (Patient P08). The mechanisms linking CoQ~10~ defect and decreased activity of MRC complexes are unknown. Studies in patients with metabolic diseases showed an increase in oxidative stress-markers and a decrease in antioxidant defences \[[@CR25]\]. More specifically, ubiquinol depletion in patient tissues may lead to increased reactive oxygen species activity \[[@CR26]\] and, since all enzymes of the MRC are susceptible to free radical induced oxidative damage \[[@CR27]\], we can hypothesize that CoQ~10~-independent MRC dysfunction may result from a high level of mitochondrial oxidative stress creating an imbalance with the CoQ~10~ antioxidant capacity, as previously evoked \[[@CR25]\]. In parallel, a possible reason for a secondary CoQ~10~ defect resulting from a primary MRC deficiency is that the enzymes involved in CoQ~10~ biosynthesis are found in a supercomplex in the inner mitochondrial membrane \[[@CR28]\]. We hypothesize that the increased oxidative stress resulting from a primary MRC deficiency may inhibit these enzymes resulting in a secondary CoQ~10~ defect.

Conclusions {#Sec6}
===========

In conclusion, our work highlights the probability that, based on spectrophotometric analysis, the frequency of CoQ~10~ disease is underestimated in routine clinical practice. Several studies, which performed a systematic CoQ~10~ quantification on muscle biopsies from pediatric and adult populations presenting a wide range of clinical phenotypes, also reported an underestimation of CoQ~10~ defects and proposed a systematic evaluation of CoQ~10~ content in all muscle biopsies \[[@CR5], [@CR29], [@CR30]\]. However, first-line CoQ~10~ quantification seems difficult to set up as a routine analysis in all diagnosis laboratories. Based on our observations, we suggest that CoQ~10~ quantification be performed in all tissues presenting a spectrophotometric deficiency of CoQ~10~-dependent enzymes, associated or not with MRC defect, regardless of the patient's age, clinical presentation or molecular diagnosis. This could prove of great value in clinical practice for the diagnosis of a disease that can be improved by CoQ~10~ supplementation.

Methods {#Sec7}
=======

Patients {#Sec8}
--------

All patients were explored in the Reference Centre for Mitochondrial Disease (CHU of Nice, France). Selection of the 18 patients was based on the following inclusion criteria: (1) availability of a muscle sample or fibroblast culture and (2) spectrophotometric deficiency of CoQ~10~-dependent activities (reduction of segments I + III or G3P + III and II + III) associated with MRC defect in muscle or in fibroblasts. The following data were systematically collected: sex, age at biopsy, age of onset, heredity, familial history, clinical presentation, brain MRI, metabolic screening, mitochondrial enzymatic studies, histological and molecular analyses. The age of onset of clinical symptoms ranged from neonatal period to 45 years of age. Blood and tissue samples were obtained after adult patients and parents of affected children had given informed consent.

Patients were divided into two groups (Table [1](#Tab1){ref-type="table"}), according to the results of molecular analysis: (1) individuals with a molecular diagnosis, carrying mutations in mtDNA or in nuclear genes and, (2) individuals with no molecular diagnosis.

Cell culture {#Sec9}
------------

Primary fibroblast cultures were obtained from patient skin punches, using standard procedures, in RPMI medium supplemented with 10 % Fetal Bovine Serum, 45 μg/ml uridine and 275 μg/ml sodium pyruvate. Cultures were incubated at 37 ℃ with 5 % CO~2~.

OXPHOS spectrophotometric measurements {#Sec10}
--------------------------------------

Enzymatic spectrophotometric measurements of the OXPHOS respiratory chain complexes and citrate synthase were performed at 37 ℃ on muscle crude homogenates or fibroblasts according to standard procedures \[[@CR31]\]. Proteins were measured according to Bradford microassay \[[@CR32]\] and results were expressed as nmole/min/mg of proteins.

Coenzyme Q~10~ quantification {#Sec11}
-----------------------------

Total coenzyme Q~10~ was extracted from tissues and analyzed by reverse phase liquid chromatography separation (column C18 symmetry 150 × 2.1 mm, 3.5 µm, Waters, France) as previously described \[[@CR33]\]. Detection and quantification were done by mass spectrometry using an API 3000 tandem mass spectrometer (ABSciex, France) equipped with an APCI source. CoQ~10~ and CoQ~9~ were analyzed in the positive mode using the following m/z 864 → 197 and 796 → 197 transitions. CoQ~9~ was used as internal standard for quantification. External calibration was performed using CoQ~10~ solutions. A stock solution was prepared by dissolving 10 mg of CoQ~10~ in 4 ml of methanol/chloroform (98:2 v/v). This solution was stable for 3 months at −80 °C. The working solutions were prepared daily by diluting the stock solution into methanol to provide a range of 0.05--1 µmol/L. The intra-assay and inter-assay CV's were, respectively, 5.7 and 6.3 % for a CoQ~10~ concentration of 0.25 µmol/L.
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